-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Caris Life Sciences, Lowers Price Target to $32

Benzinga·05/08/2026 10:36:57
Listen to the news
BTIG analyst Mark Massaro maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and lowers the price target from $38 to $32.